{"id":492258,"date":"2025-10-27T01:53:12","date_gmt":"2025-10-27T01:53:12","guid":{"rendered":"https:\/\/www.europesays.com\/fr\/492258\/"},"modified":"2025-10-27T01:53:12","modified_gmt":"2025-10-27T01:53:12","slug":"novartis-achete-avidity-biosciences-pour-12-milliards-de-dollars","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/fr\/492258\/","title":{"rendered":"Novartis ach\u00e8te Avidity Biosciences pour 12\u00a0milliards de dollars"},"content":{"rendered":"<p>\n    Le g\u00e9ant suisse de la pharmacie va acqu\u00e9rir cette soci\u00e9t\u00e9 californienne sp\u00e9cialis\u00e9e dans le traitement de maladies g\u00e9n\u00e9tiques touchant les muscles, gr\u00e2ce \u00e0 l\u2019ARN messager.<\/p>\n<p class=\"fig-paragraph\">Le g\u00e9ant pharmaceutique suisse\u00a0<a href=\"http:\/\/www.lefigaro.fr\/flash-eco\/novartis-voit-son-benefice-net-grimper-de-29-au-premier-semestre-20250717\" target=\"_blank\" data-fig-type=\"NewsFlash\" rel=\"noopener\" data-gtm-custom-categorie=\"navigation\" data-gtm-custom-action=\"crossclick\" data-gtm-custom-label=\"Contextuel\" data-gtm-event=\"customEventSPE\" data-fig-domain=\"LEFIGARO\">Novartis<\/a>\u00a0a annonc\u00e9 dimanche avoir conclu un accord pour acqu\u00e9rir Avidity Biosciences, une soci\u00e9t\u00e9 biopharmaceutique bas\u00e9e \u00e0 San Diego, en\u00a0<a href=\"http:\/\/www.lefigaro.fr\/international\/redecoupage-electoral-aux-etats-unis-la-californie-prete-a-imiter-le-texas-20251020\" target=\"_blank\" data-fig-type=\"Article\" rel=\"noopener\" data-gtm-custom-categorie=\"navigation\" data-gtm-custom-action=\"crossclick\" data-gtm-custom-label=\"Contextuel\" data-gtm-event=\"customEventSPE\" data-fig-domain=\"LEFIGARO\">Californie<\/a>, et valoris\u00e9e, dans cette transaction, \u00e0 12\u00a0milliards de dollars. C\u2019est la plus grosse acquisition pour le groupe depuis que Vas Narasimhan en est devenu le PDG, en 2018, souligne le Financial Times. La valeur en Bourse, sur le Nasdaq, \u00e9tait, vendredi, de 6,7\u00a0milliards de dollars, ce qui conf\u00e8re une prime de 46\u00a0% pour les actionnaires.<\/p>\n<p class=\"fig-paragraph\">\u00ab\u00a0L\u2019accord une fois finalis\u00e9 devrait permettre la cr\u00e9ation d\u2019un g\u00e9ant de l\u2019industrie (pharmaceutique, NDLR), s\u2019appuyant sur l\u2019expertise de Novartis en mati\u00e8re d\u2019atrophie musculaire spinale et sur ses capacit\u00e9s de commercialisation dans les maladies neuromusculaires g\u00e9n\u00e9tiques\u00a0\u00bb, a d\u00e9clar\u00e9 Novartis dans un communiqu\u00e9.<\/p>\n<p>                                    <a class=\"fig-a11y-skip a11y-hidden\" href=\"#fig-a11y-skip-main-inarticle\"><br \/>\n        Passer la publicit\u00e9<br \/>\n    <\/a><\/p>\n<p class=\"fig-paragraph\">Avidity Biosciences est une soci\u00e9t\u00e9 de biopharmacie qui s\u2019est sp\u00e9cialis\u00e9e dans le traitement de maladies g\u00e9n\u00e9tiques neuromusculaires. Elle met au point des traitements \u00e0 base d\u2019ARN messager, la technique qui a fait le succ\u00e8s des vaccins anti-Covid. La ma\u00eetrise de la technique de l\u2019ARN messager par Avidity Biosciences devrait permettre \u00e0 Novartis d\u2019acc\u00e9l\u00e9rer sa strat\u00e9gie dans les neurosciences.<\/p>\n<p class=\"fig-paragraph\">L\u2019an dernier, Novartis a enregistr\u00e9 un chiffre d\u2019affaires de 50\u00a0milliards de dollars, en hausse de 12\u00a0%.<\/p>\n","protected":false},"excerpt":{"rendered":"Le g\u00e9ant suisse de la pharmacie va acqu\u00e9rir cette soci\u00e9t\u00e9 californienne sp\u00e9cialis\u00e9e dans le traitement de maladies g\u00e9n\u00e9tiques&hellip;\n","protected":false},"author":2,"featured_media":492259,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[61008,35,33,34,1011,27,22747,11025,15299],"class_list":{"0":"post-492258","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-economie","8":"tag-arn-messager","9":"tag-business","10":"tag-economie","11":"tag-economy","12":"tag-fr","13":"tag-france","14":"tag-genetique","15":"tag-novartis","16":"tag-pharmacie"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@fr\/115443636878918206","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/posts\/492258","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/comments?post=492258"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/posts\/492258\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/media\/492259"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/media?parent=492258"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/categories?post=492258"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/tags?post=492258"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}